|CTI Life Sciences Fund II||Venture Partner||Canada|
UNDER PRESSURE: HOW DOES THE URGE TO BRING RARE DISEASE THERAPIES CREATE A NEW RANGE OF BUSINESS OR COLLABORATIVE MODELS?
Anjan or “AJ” Aralihalli is currently Chief Business Officer of GLyPharma Therapeutic, a Canadian biotechnology company focused on rare GI disorders. He is also a Venture Partner at CTI Life Sciences, a leading Canadian venture fund and is a steering committee member of a NYC based angel investment group called Mid-Atlantic Bio Angels (MABA). Anjan is also a corporate fundraiser for two ALS charities, Wings Over Wall Street (a division of the Muscular Dystrophy Association) and The Robert Packard Center for ALS Research at Johns Hopkins University.
Previously, he worked at a variety of biotechs and pharma companies including Neurochem, Abbott, Sanofi, Shionogi and ActoGeniX. He has 20+ years of international experience across a number of functions including investor relations, corporate development, venture and angel financing, in & out-licensing, strategic alliances, alliance management, new product development, sales, marketing, & clinical trial management.
He received his BSc from Concordia University, MBA from Queen’s University (both in Canada) and is currently completing his MSc in Biotechnology at Johns Hopkins University.